表皮生长因子受体酪氨酸激酶抑制剂研究进展  

Epidermal growth factor receptor tyrosine kinase inhibitors:research advances

作　　者：李佳琦[1] 姚艳艳 滕玉双 卢兆晨 宫畅 宗哲 董雷[1] LI Jia-qi;YAO Yan-yan;TENG Yu-shuang;LU Zhao-chen;GONG Chang;ZONG Zhe;DONG Lei(Department of Pharmacy, The First Hospital of Jilin University, Changchun 130021, China)

机构地区：[1]吉林大学第一医院药学部

出　　处：《国际药学研究杂志》2019年第1期1-9,共9页Journal of International Pharmaceutical Research

基　　金：吉林省科技厅发展计划资助项目(20190201053JC)

摘　　要：表皮生长因子受体(EGFR)是一类具有酪氨酸激酶活性的细胞膜表面受体,其介导的信号转导与肿瘤细胞的生长、增殖、分化、凋亡、转移等过程密切相关。研究表明,通过抑制EGFR可有效抑制肿瘤的生长。近年来,开发出许多以EGFR为靶点的药物,靶向EGFR酪氨酸激酶抑制剂已成为抗肿瘤药物研究的一个热点,目前EGFR酪氨酸激酶抑制剂已经逐渐应用于临床。本文主要对近年来以EGFR酪氨酸激酶为靶点的抑制剂的研究进展进行综述。Epidermal growth factor receptor(EGFR),a receptor on the cell membrane surface,has tyrosine kinase activity.The signal transduction mediated by EGFR is closely related to the growth,proliferation,differentiation,apoptosis and metastasis of tumor cells. Studies have shown that the tumor growth could be inhibited by inhibiting EGFR. In recent years,many drugs targeting EGFR have been developed. Inhibitors targeting EGFR tyrosine kinase have become a hotspot in the research of antitumor drugs. At present,EGFR tyrosine kinase inhibitors have been gradually applied in clinical practice. This paper mainly reviews the research progress in the EGFR tyrosine kinase inhibitors in recent years.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 抗肿瘤药 

分 类 号：R979.1[医药卫生—药品]